Compare Torrent Pharma with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs SANOFI INDIA - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA SANOFI INDIA TORRENT PHARMA/
SANOFI INDIA
 
P/E (TTM) x 58.4 34.8 167.6% View Chart
P/BV x 6.2 6.1 101.2% View Chart
Dividend Yield % 0.8 1.4 58.1%  

Financials

 TORRENT PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
SANOFI INDIA
Dec-18
TORRENT PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,5506,840 22.7%   
Low Rs1,1444,630 24.7%   
Sales per share (Unadj.) Rs354.71,203.1 29.5%  
Earnings per share (Unadj.) Rs40.1165.3 24.2%  
Cash flow per share (Unadj.) Rs64.2209.9 30.6%  
Dividends per share (Unadj.) Rs14.0084.00 16.7%  
Dividend yield (eoy) %1.01.5 71.0%  
Book value per share (Unadj.) Rs273.1963.6 28.3%  
Shares outstanding (eoy) m169.2223.03 734.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.84.8 79.7%   
Avg P/E ratio x33.634.7 96.8%  
P/CF ratio (eoy) x21.027.3 76.7%  
Price / Book Value ratio x4.96.0 82.8%  
Dividend payout %34.950.8 68.7%   
Avg Mkt Cap Rs m227,897132,078 172.5%   
No. of employees `00014.73.3 445.3%   
Total wages/salary Rs m11,3534,068 279.1%   
Avg. sales/employee Rs Th4,083.08,393.8 48.6%   
Avg. wages/employee Rs Th772.31,232.4 62.7%   
Avg. net profit/employee Rs Th461.31,153.0 40.0%   
INCOME DATA
Net Sales Rs m60,02127,708 216.6%  
Other income Rs m2,988897 333.2%   
Total revenues Rs m63,00928,605 220.3%   
Gross profit Rs m13,4936,235 216.4%  
Depreciation Rs m4,0861,027 397.9%   
Interest Rs m3,0857 44,068.6%   
Profit before tax Rs m9,3106,098 152.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,5292,292 110.3%   
Profit after tax Rs m6,7813,806 178.2%  
Gross profit margin %22.522.5 99.9%  
Effective tax rate %27.237.6 72.3%   
Net profit margin %11.313.7 82.3%  
BALANCE SHEET DATA
Current assets Rs m52,62315,922 330.5%   
Current liabilities Rs m52,0226,235 834.3%   
Net working cap to sales %1.035.0 2.9%  
Current ratio x1.02.6 39.6%  
Inventory Days Days12064 187.9%  
Debtors Days Days7621 365.3%  
Net fixed assets Rs m85,0167,539 1,127.7%   
Share capital Rs m846230 367.9%   
"Free" reserves Rs m45,37621,962 206.6%   
Net worth Rs m46,22222,192 208.3%   
Long term debt Rs m41,1150-   
Total assets Rs m142,43229,839 477.3%  
Interest coverage x4.0872.1 0.5%   
Debt to equity ratio x0.90-  
Sales to assets ratio x0.40.9 45.4%   
Return on assets %6.912.8 54.2%  
Return on equity %14.717.2 85.5%  
Return on capital %14.227.5 51.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,5807,587 192.2%   
Fx outflow Rs m3,6007,145 50.4%   
Net fx Rs m10,980442 2,484.2%   
CASH FLOW
From Operations Rs m8,9423,739 239.1%  
From Investments Rs m-47,070-731 6,439.1%  
From Financial Activity Rs m34,174-1,972 -1,733.0%  
Net Cashflow Rs m-3,6551,036 -352.8%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 7.0 14.4 48.8%  
FIIs % 12.6 14.6 86.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 10.5 83.8%  
Shareholders   26,511 15,184 174.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Tata Motors & ONGC Climb 5%(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Investors are cautious ahead of the release of Consumer Price Index-based inflation.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Oct 14, 2019 01:09 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS